Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer

• Upal Basu Roy, PhD, MPH,
• Anne-Marie Baird, PhD,
• Andrew Ciupek, PhD,
• Jesme Fox, MbChB, MBA,
• Eugene Manley, Jr., PhD,
• Kim Norris,
• Giorgio V. Scagliotti, MD, PhD,
• Heather A. Wakelee, MD,
• Tetsuya Mitsudomi, MD,
• Russell J. Clark, JD,
• Renee Arndt, MS,
• Fred R. Hirsch, MD, PhD,
• Paul A. Bunn, MD,
• Matthew P. Smeltzer, PhD

Affiliations

Upal Basu Roy, PhD, MPH

LUNGevity Foundation, Bethesda, Maryland; Corresponding author. Address for correspondence: Upal Basu Roy, PhD, MPH, LUNGevity Foundation, 6917 Arlington Road, Bethesda, MD 20814.

Anne-Marie Baird, PhD

Lung Cancer Europe and Trinity College, Dublin, Ireland

Andrew Ciupek, PhD

GO2 Foundation for Lung Cancer, Washington, District of Columbia

Jesme Fox, MbChB, MBA

Roy Castle Lung Cancer Foundation, Liverpool, United Kingdom

Eugene Manley, Jr., PhD

Lung Cancer Research Foundation, New York, New York

Kim Norris

Lung Cancer Foundation of America, New Ulm, Minnesota

Giorgio V. Scagliotti, MD, PhD

A.O.U. San Luigi Gonzaga Hospital, University of Torino, Orbassano, Italy

Heather A. Wakelee, MD

Stanford University, Palo Alto, California

Tetsuya Mitsudomi, MD

Kindai University Faculty of Medicine, Osaka-Sayama, Japan

Russell J. Clark, JD

Cancer Technology Applications, LLC, San Diego, California

Renee Arndt, MS

Cancer Technology Applications, LLC, San Diego, California

Fred R. Hirsch, MD, PhD

Icahn School of Medicine at Mount Sinai, New York, New York

Paul A. Bunn, MD

University of Colorado School of Medicine, Aurora, Colorado

Matthew P. Smeltzer, PhD

Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee